TNF-α-induced insulin resistance in vivo and its prevention by troglitazone

Diabetes

Volumn 46, Issue 11, 1997, Pages 1678-1683

  Miles, Philip D G ^a,d   Romeo, Oreste M ^a   Higo, Katsuya ^a   Cohen, Aaron ^a   Rafaat, Karim ^a   Olefsky, Jerrold M ^b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; INSULIN; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FATTY ACID METABOLISM; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; INSULIN RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0030661983     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.11.1678     Document Type: Article

References (35)

1. Choy LN, Rosen BS, Spiegelman BM; Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 267:12736-12741, 1992
2. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
3. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB: The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111-2119, 1995
4. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409-2415, 1995
5. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM: Tumor necrosis factor α inhibits signaling from insulin receptor. Proc Natl Acad Sci USA 91:4854-4858, 1994
6. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A: Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268:26055-26058, 1993
7. Van Der Poll T, Romijn JA, Endert E, Borm JJ, Büller HR, Sauerwein HP: Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 261:E457-E465, 1991
8. Douglas RG, Gluckman PD, Breier BH, McCall JL, Parry B, Shaw JH: Effects of recombinant IGF-I on protein and glucose metabolism in rTNF-infused lambs. Am J Physiol 261:E606-E612, 1991
9. Lang CH, Dobbrescu C, Bagby GJ: Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130:43-52, 1992
10. Iwamoti Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I: Effects of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083-10806, 1991
11. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
12. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
13. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
14. Fujiwara T, Wada M, Fukuda K, Fukami M, Yorhioka S, Yoshioka T, Horikoshi H: Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure in C57BL/KsJ-db/db mice. Metabol 40:1213-1218, 1991
15. Lee M, Miles PDG, Khoursheed M, Gao K, Moossa AR, Olefsky JM: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43:1435-1439, 1994
16. Desbuquois B, Aurbach GD: Use of polyethylene glycol to separate free and antibody-bound peptide hormone in radioimmunoassays. J Clin Endocrin Metabol 33:732-738, 1971
17. Revers RR, Fink R, Griffin J, Olefsky JM, Kolterman OG: Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. J Clin Invest 73:664-672, 1984
18. Freidenberg GR, Suter SL, Henry RR, Reichart D, Olefsky JM: In vivo stimulation of insulin receptor kinase in human skeletal muscle: correlation with insulin-stimulated glucose disposal during euglycemic clamp studies. J Clin Invest 87:2222-2229, 1991
19. Steele R: Influence of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82:420-430, 1959
20. Ferrannini E, Barret EJ, Bevilacqua S, DeFronzo RA: Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72:1737-1747, 1983
21. Svedburg J, Bjorntorp P, Smith U, Lonnroth P: Free-fatty acid inhibition of insulin binding, degradation, and action in isolated rat hepatocytes. Diabetes 39:570-574, 1990
22. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet i:785-789, 1963
23. Torti FM, Diechmann B, Beutler B, Cerami A, Ringold GM: A macrophage factor inhibits adipocyte gene expression; an in vitro model of cachexia. Science 229:867-869, 1985
24. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF - and obesity-induced insulin resistance. Science 271:665-668, 1996
25. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM: Tumor necrosis factor (TNF)-α inhibits insulin signaling through stimulation of p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 271:13018-13022, 1996
26. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM: Reduced tyrosine activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-α. J Clin Invest 94:1543-1549, 1994
27. Stephens JM, Pekala PH: Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem 266:21839-21845, 1991
28. Cornelius P, Lee MD, Marlowe M, Pekala PH: Monokine regulation of glucose transporter mRNA in L6 myotubes. Biochem Biophys Res Commun 165:429-136, 1989
29. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Wilson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor δ (PPARδ). J Biol Chem 270:12953-12956, 1995
30. Miyata KS, McCaw SE, Marcus SL, Rachubinski RA, Capone JP: The peroxisome proliferator-activated receptor interacts with the retinoid X receptor in vivo. Gene 148:327-330, 1994
31. Gearing KL, Gottlicher M, Teboul M, Widmark E, Gustafeson JA: Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA 90:1440-1444, 1993
32. Krey G, Mahfoudi A, Wahli W: Functional interactions of peroxisome proliferator-activated receptor, retinoid-X receptor, and Sp1 in the transcriptional regulation of the acyl-coenzyme-A oxidase promoter. Mol Endocrinol 9:219-231, 1995
33. Mukherjee R, Jow L, Noonan D, McDonnell DP: Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steriod Biochem Mol Biol 51:157-166, 1994
34. Braissnt O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat Endocrinology 137:354-366, 1996
35. Ciaraldi TP, Huber-Knudsen K, Hickman M, Olefsky JM: Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metab Clin Exp 44:976-981, 1995